These have shown that, in patients without other comorbid conditions, treatment for from 6 to 12 months with a combination of interferon-alpha-2b, 3 MU three times a week (ttw), plus ribavirin ...
in patients with a low risk of recurrence but may have a better tolerability profile. The drug has shown promise in combination regimens with BCG and interferon- -2b.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback